Market spiral pricing of cancer drugs

Cancer

Volumn 119, Issue 22, 2013, Pages 3900-3902

  Light, Donald W ^a   Kantarjian, Hagop ^b  

^a HARVARD UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANTINEOPLASTIC AGENT; AXITINIB; BOSUTINIB; CABOZANTINIB; CARBOXYPEPTIDASE G2; CARFILZOMIB; ENZALUTAMIDE; HOMOHARRINGTONINE; PERTUZUMAB; PLACEBO; PONATINIB; REGORAFENIB; SORAFENIB; UNCLASSIFIED DRUG; VINCRISTINE SULFATE; VISMODEGIB; VORAXASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; BASAL CELL CARCINOMA; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DRUG APPROVAL; DRUG COST; DRUG DOSE INCREASE; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MARKETING; DRUG RESEARCH; DRUG TOXICITY; HUMAN; KIDNEY CARCINOMA; METHOTREXATE TOXICITY; MULTIPLE MYELOMA; NOTE; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; THYROID MEDULLARY CARCINOMA;

ANTINEOPLASTIC AGENTS; COSTS AND COST ANALYSIS; DRUG COSTS; DRUG INDUSTRY; HEALTH CARE SECTOR; HUMANS; NEOPLASMS; UNITED STATES;

EID: 84887031063     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28321     Document Type: Note

References (13)

1. Kantarjian HM, Fojo T, Mathisen M, Zwelling LA,. Cancer drugs in the United States: Justum Pretium - The just price. J Clin Oncol. 2013;doi: 10.1200/JCO.2013.49.1845.
2. DiMasi JA, Hansen RW, Grabowski HG,. The price of innovation: new estimates of drug development costs. J Health Econ. 2003; 22: 151-185.
3. Vernon JA, Golec JH, Dimasi JA,. Drug development costs when financial risk is measured using the Fama-French three-factor model. Health Econ. 2010; 19: 1002-1005.
4. Light DW, Warburton RN,. Demythologizing the high cost of pharmaceutical research. Biosocieties. 2011; 6: 1-17.
5. Light DW,. Basic research funds to discover important new drugs: who contributes how much? In:, Burke MA, ed. Monitoring the Financial Flows for Health Research 2005: Behind the Global Numbers. Geneva, Switzerland: Global Forum for Health Research; 2006: 27-43.
6. Light DW, Lexchin J,. Foreign free riders and the high price of US medicines. BMJ. 2005; 331: 958-960.
7. Silverman, E., Quote of the.Year? $1B Drug Cost Is 'A Myth'. Pharmalot. http://www.pharmalive.com/quote-year-1b-drug-cost-myth. Posted March 18, 2013. Accessed July 17, 2013.
8. Keyhani S, Diener-West M, Powe N,. Do drug prices reflect development time and government investment? Med Care. 2005; 43: 753-762.
9. Schondelmeyer S, Purvis L,. Rx Price Watch Report, March 2012: Trends in Retail Prices of Prescription Drugs Widely Used by Medicare Beneficiaries 2005 to 2009. Washington, DC: American Association of Retired Persons; 2012.
10. Light D, Lexchin J,. Pharmaceutical R&D-what do we get for all that money? BMJ. 2012; 344: e4348
11. O'Sullivan J, Chaikind H, Tilson S, Boulanger J, Morgan P,. Specialists and analyst in social legislation. Domestic social policy division. CRS report for Congress: Overview of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Updated December 6, 2004. Washington, DC: Library of Congress. http://royce.house.gov/uploadedfiles/overview%20of%20medicare.pdf. Accessed July 17, 2013.
12. Rome E,. Big pharma CEOs rake in $1.57 billion in pay. Huff Post Business. 2013. http://www.huffingtonpost.com/ethan-rome/big-pharma-ceo-pay-b- 3236641.html. Accessed July 17, 2013.
13. Baker D,. The savings from an Efficient Medicare Prescription Drug Plan. Center for Economic and Policy Research. http://www.cepr.net/documents/ efficient-medicare-2006-01.pdf. Accessed July 17, 2013.